$ 21.8
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of VERA is 67 and suggests 207% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
